Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) has announced the publication of its Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025. This announcement was made on February 06, 2026, and the results were published in the Financial Express (English Edition) and Vishwavani (Kannada Edition). The company has also provided details regarding a significant business transaction involving a potential acquisition. Anthem Biosciences is proposing to acquire 100% of the equity share capital of a Target Company for a consideration of ₹40 Lakhs (0.4 Crore). This acquisition is subject to regulatory approvals and is expected to be completed within 90 days from the date of the Board approval. The company has also entered into a Memorandum of Understanding (MoU) with a Target Company for the acquisition of its business, with a proposed consideration of ₹17 Lakhs (0.17 Crore). Furthermore, Anthem Biosciences is planning to acquire 100% equity shares of another Target Company for ₹17 Lakhs (0.17 Crore), subject to regulatory approvals. The company has also announced the acquisition of another Target Company for ₹40 Lakhs (0.4 Crore). The Board of Directors has approved the acquisition of 100% equity shares of a Target Company for ₹40 Lakhs (0.4 Crore). In a separate development, Anthem Biosciences is also involved in a legal dispute concerning the recovery of ₹30 Crore. The company has filed a suit for recovery against a Defendant, and the case is scheduled for the next hearing on February 13, 2026. The court will hear the case at 5:25 PM, with a final hearing expected on February 20, 2026. The company is actively pursuing the recovery of the claimed amount. Additionally, Anthem Biosciences has announced a significant business development involving the acquisition of a Target Company for ₹17 Lakhs (0.17 Crore) by its subsidiary, Anthem Life Sciences Private Limited. This acquisition is subject to regulatory approvals and is expected to be completed within 90 days from the date of Board approval. The company has also announced the acquisition of 100% equity shares of a Target Company for ₹17 Lakhs (0.17 Crore). Lastly, Anthem Biosciences has announced a proposed acquisition of 100% shares of a Target Company for ₹30 Crores. The Board of Directors has approved the acquisition of 100% equity shares of a Target Company for ₹30 Crores. This acquisition is subject to regulatory approvals and is expected to be completed within 90 days from the date of Board approval. The company has also announced the acquisition of 100% equity shares of a Target Company for ₹30 Crores.
